CDNA CAREDX INC

CareDx to Report Fourth Quarter and Full Year 2020 Financial Results

CareDx to Report Fourth Quarter and Full Year 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday, February 24, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 877-705-6003 for domestic callers or 201-493-6725 for international callers. Please reference Conference ID: 13715410. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: .

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: .

CONTACTS:

Greg Chodaczek

347-620-7010



EN
12/02/2021

Underlying

CDNACAREDX INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CAREDX INC

Jonathan Moreland
  • Jonathan Moreland
Free Trial
SHEN Shenandoah Tele...
CDNA CAREDX INC ... (+10)

InsiderInsights.com Daily Ratings Report: September 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
CDNA CAREDX INC
AROW ARROW FINANCIAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
DLHC DALEIGH HOLDINGS CORP
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
HYMC HYCROFT MINING HOLDING CORPORATION
09/15/25 September 15, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
SHEN Shenandoah Tele...
SBH Sally Beauty Ho... ... (+44)

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SBH SALLY BEAUTY HOLDINGS INC.
PRGO PERRIGO CO. PLC
NVCR NOVOCURE LTD.
KURA KURA ONCOLOGY INC.
GLP GLOBAL PARTNERS LP
FRPT FRESHPET INC
FLDM FLUIDIGM
FCN FTI CONSULTING INC.
CPRX CATALYST PHARMACEUTICALS
CE CELANESE CORPORATION
CDNA CAREDX INC
ASA ASA
AROW ARROW FINANCIAL CORP.
MDU MDU RESOURCES GROUP INC
ADC AGREE REALTY CORPORATION
CECE CECO ENVIRONMENTAL CORP.
ESP ESPEY MANUFACTURING & ELECTRONICS CORP.
BHB BAR HARBOR BANKSHARES
MFIN MEDALLION FINANCIAL CORP.
BSM BLACK STONE MINERALS LP
PLSE PULSE BIOSCIENCES
MLP MAUI LAND & PINEAPPLE CO. INC.
CELC CELCUITY
BRT BRT APARTMENTS
CCEL CRYO-CELL INTERNATIONAL
AEYE AUDIOEYE INC
DLHC DALEIGH HOLDINGS CORP
OPCH OPTION CARE HEALTH INC
SMMT SUMMIT THERAPEUTICS INC
CTO CONSOLIDATED-TOMOKA LAND CO
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
NAUT NAUTILUS BIOTECHNOLOGY INC
ENOV ENOVIS CORPORATION
PFHC PROFRAC HLDG CORP
MLYS MINERALYS THERAPEUTICS INC
PROP PRAIRIE OPERATING CO.
DMA DESTRA MULTI ALTERNATIVE FUND
CAMP CAMP4 THERAPEUTICS CORPORATION
SFD SMITHFIELD FOODS INC.
AFCG AFC GAMMA
HYMC INC.
NIQ HYCROFT MINING HOLDING CORPORATION
NIQ GLOBAL INTELLIGENCE PLC
09/15/25 September 15, 2025 1 EN
Free Trial
CDNA CAREDX INC

CareDx Inc: 1 director

A director at CareDx Inc sold 16,700 shares at 14.128USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

05/08/25 May 8, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.45
MDWD MEDIWOUND
EBS Emergent BioSol... ... (+20)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

MDWD MEDIWOUND
EBS EMERGENT BIOSOLUTIONS INC.
CDNA CAREDX INC
THS TREEHOUSE FOODS INC.
FONR FONAR CORP.
KIDS ORTHOPEDIATRICS CORP
AMD ADVANCED MICRO DEVICES INC.
KRYS KRYSTAL BIOTECH INC
MMMB MAMAMANCINI'S HOLDINGS INC
SITM SITIME
RNA AVIDITY BIOSCIENCES
PWP PERELLA WEINBERG PARTNERS
ASTS AST SPACEMOBILE INC
BRBR BELLRING BRANDS INC
INTR INTER & CO INC
EWTX EDGEWISE THERAPEUTICS INC
ACRV ACRIVON THERAPEUTICS INC
WGS GENEDX HOLDINGS CORP.
XPOF XPONENTIAL FITNESS INC
SOWG SOW GOOD INC
07/08/24 July 8, 2024 1 EN
 PRESS RELEASE
Free
CDNA CAREDX INC

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell ...

CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoieti...

May 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch